- The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved GW Pharmaceuticals' cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) for patients two years of age and older.
- GW is a part of Jazz Pharmaceuticals plc JAZZ. Epidiolex/Epidyolex (cannabidiol) is a prescription, plant-derived cannabis-based medicine.
- Concurrently, Jazz and Stand Up To Cancer (SU2C) have announced a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
- The collaboration between the companies will provide SU2C-funded researchers access to two Jazz molecules and funds to support one or more research projects over three years.
- The collaboration may also support non-clinical studies of an investigational pan-RAF inhibitor compound called JZP815 in RAF- and RAS-mutated solid cancers.
- Price Action: JAZZ shares are up 2.4% at $147.36 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
- Photo by Rex Medlen from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.